Evidence map›Paper›PMID 35566799›Full record

ArticleJournal of clinical medicine2022

Standardization of Post-Vitrification Human Blastocyst Expansion as a Tool for Implantation Prediction.

Anat Hershko-Klement, Shaul Raviv, Luba Nemerovsky, Tal Rom, Ayelet Itskovich, Danit Bakhshi, Adrian Shulman, Yehudith Ghetler

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anat Hershko-KlementThe IVF Unit, Department of Obstetrics and Gynecology, Hadassah Mt Scopus, The Hebrew University of Jerusalem, Jerusalem 91240, Israel.ORCID 0000-0002-0330-5470
Shaul RavivThe IVF Unit, Meir Medical Center, Department of Obstetrics and Gynecology, Affiliated to Sackler School of Medicine, Tel Aviv University, Kfar Saba 44281, Israel.
Luba NemerovskyThe IVF Unit, Meir Medical Center, Department of Obstetrics and Gynecology, Affiliated to Sackler School of Medicine, Tel Aviv University, Kfar Saba 44281, Israel.
Tal RomThe IVF Unit, Meir Medical Center, Department of Obstetrics and Gynecology, Affiliated to Sackler School of Medicine, Tel Aviv University, Kfar Saba 44281, Israel.
Ayelet ItskovichThe IVF Unit, Meir Medical Center, Department of Obstetrics and Gynecology, Affiliated to Sackler School of Medicine, Tel Aviv University, Kfar Saba 44281, Israel.
Danit BakhshiThe IVF Unit, Meir Medical Center, Department of Obstetrics and Gynecology, Affiliated to Sackler School of Medicine, Tel Aviv University, Kfar Saba 44281, Israel.
Adrian ShulmanThe IVF Unit, Meir Medical Center, Department of Obstetrics and Gynecology, Affiliated to Sackler School of Medicine, Tel Aviv University, Kfar Saba 44281, Israel.
Yehudith GhetlerThe IVF Unit, Meir Medical Center, Department of Obstetrics and Gynecology, Affiliated to Sackler School of Medicine, Tel Aviv University, Kfar Saba 44281, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increased use of vitrified blastocysts has encouraged the development of various criteria for selecting the embryo most likely to implant. Post-thaw assessment methods and timetables vary among investigators. We investigated the predictive value of well-defined measurements of human blastocyst re-expansion, following a fixed incubation period. Post-thaw measurements were taken exactly at 0 and 120 ± 15 min. Minimum and maximum cross-sectional axes were measured. Three groups were defined: Group 1: embryos that continued to shrink by 10 µm or more; group 2: embryos that ranged from -9 to +9 µm; and group 3: re-expansion of 10 µm or more. Patient and morphokinetic data were collected and integrated into the analysis. A total of 115 cases were included. The clinical pregnancy rate for group 1 was 18.9%; group 2, 27%; and group 3, 51.2% (

Indexed as

blastocystexpansionin vitro fertilizationpregnancy ratevitrification

Identifiers

PMID35566799
PMCPMC9101782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.